New malaria vaccine trial aims to protect mothers and babies in mali
NCT ID NCT06080243
First seen Feb 28, 2026 · Last updated May 24, 2026 · Updated 10 times
Summary
This study tests the R21/Matrix-M1 malaria vaccine in 330 healthy women aged 18–35 in Mali who plan to become pregnant. Participants receive two or three doses of the vaccine or a placebo, and are followed for two years to check safety, immune response, and how well the vaccine prevents malaria. Women who become pregnant are also monitored to see if the vaccine protects them and their babies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY WOMEN OF CHILD BEARING POTENTIAL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Koumantou Study Clinic
Bougouni, Sikasso, Mali
Conditions
Explore the condition pages connected to this study.